2A Biosciences

About 2A Biosciences

2A Biosciences is the first to unlock serotonin 2A receptor biology for neuro-regeneration, neuroprotection, and inflammation resolution. Founded based on the breakthrough discovery of Dr. Charles Nichols that certain psychedelics are potent anti-inflammatories, 2A Biosciences has uncovered how to structure these drugs without behavioral or safety liabilities, while maximizing therapeutic outcomes. 2A Biosciences is currently focused on transforming neuropathic and neurodegenerative disease treatment with first-in-class and best-in-class nerve regeneration for millions of patients worldwde.

Tagged with

Mental Health & WellnessHealthcareBiotechnology

Team

Alex Speiser

Employee

Problem statement

Neuropathic and neurodegenerative diseases represent a broad and growing global health crisis
- $800B annual economic burden in the U.S.
- 1 in 4 people worldwide experience vision impairment
- Over 1 in 3 people are affected by neurological diseases, the leading cause of illness and disability worldwide
- Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds

Yet no treatments exist to modify or halt these diseases, highlighting huge need for novel solutions.

Milestones

November 2026

Human Clinical Trials (Nerve Regeneration)

On track to begin clinical trials

August 2025

IND-Enabling Studies (Advancing to Clinical Trials)

Advancing towards human clinical trials through IND-enabling studies.

November 2024

Nerve Regeneration in Animals

Breakthrough nerve regeneration through promotion of nerve growth factor and neuroplasticity. Extremely potent at small concentrations of drugs. Huge potential across therapeutic areas and diseases.

November 2023

Hired COO/CDO Dr. Allan Shepard

4 IND enabling development programs experience and 10 clinical trials run. Ex-Alcon and big pharma. Launched 2A Biosciences’ ophthalmology program.

March 2023

Seed Round

Raised $5.25M from leading psychedelic investors and family offices.

October 2022

Company Foundation

Established company with co-founders Dr. Charles Nichols, Dr. David Nichols, Dr. Timothy Foster, and Alex Speiser.

Dr. David Nichols defined serotonin 2A receptors’ therapeutic role in psychiatry, publishing the first paper on MDMA, and responsible for psychedelic IP being used in the clinic today (i.e. Compass Pathways).

Charles discovered 2A activation drives potent anti-inflammatory effects in asthma, cardiovascular, and autoimmune disease models, building upon his earlier efficacy work in models of neuropsychology.

With Dr. Timothy Foster, they confirmed 2A’s therapeutic impact in further inflammatory, ocular, and neurodegenerative disease models.

Updates

Alex Speiser has visited this profile using a private link.

Added 2 days ago

Alex Speiser has visited this profile using a private link.

Added 4 days ago

Alex S has visited this profile using a private link.

Added 5 days ago